{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:41:12Z","timestamp":1792442472179,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["K23HL155898"],"award-info":[{"award-number":["K23HL155898"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Down syndrome regression disorder (DSRD) causes a rapid loss of cognitive, behavioral, and daily living skills, usually in adolescents and young adults with Down syndrome. Because people with Down syndrome have a high lifetime risk of Alzheimer\u2019s disease, we examined whether DSRD is associated with an Alzheimer-related pattern of tau pathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, single-center study, we measured plasma phosphorylated tau-217 (p-tau217), a blood marker of Alzheimer pathology, in 132 participants: 48 with DSRD, 39 with Down syndrome without regression (DSwR), and 45 neurodevelopmental controls. We compared p-tau217 concentrations across groups and examined relationships with demographic factors, medical conditions, treatment status, and diagnostic test abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median p-tau217 concentrations were similar in the DSRD (0.082\u2009pg\/mL), DSwR (0.084\u2009pg\/mL), and neurodevelopmental control (0.080\u2009pg\/mL) groups (overall comparison,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2009=\u2009\u20090.57). Pairwise comparisons and models accounting for demographic and clinical factors also showed no statistically significant group differences. Among participants with DSRD, p-tau217 was not associated with treatment status or abnormalities on brain-wave testing, neuroimaging, or cerebrospinal fluid analysis. No clinical or demographic factor remained associated with p-tau217 after accounting for the number of analyses performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings provide no evidence of a group-level Alzheimer-related p-tau217 elevation in young people with DSRD and support DSRD as a condition distinct from Alzheimer\u2019s disease. However, a single blood measurement cannot exclude Alzheimer pathology in an individual. Longitudinal studies using several complementary biomarkers are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01921-y","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:03:22Z","timestamp":1789963402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phosphorylated tau 217 in young adults with Down syndrome and Down syndrome regression disorder"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abdel-Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhik K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4147-5395","authenticated-orcid":false,"given":"Lilia","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2689-9841","authenticated-orcid":false,"given":"Samuel T.","family":"Otey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-1546","authenticated-orcid":false,"given":"Mariam M.","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4802-3788","authenticated-orcid":false,"given":"Maeve C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinayida","family":"Schlachetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/ajmg.a.62922","volume":"188","author":"SL Santoro","year":"2022","unstructured":"Santoro, S. L. et al. Unexplained regression in Down syndrome: management of 51 patients in an international patient database. Am. J. Med. Genet. A 188, 3049\u20133062 https:\/\/doi.org\/10.1002\/ajmg.a.62922 (2022).","journal-title":"Am. J. Med. Genet. A"},{"key":"1921_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-023-09503-y","volume":"15","author":"NK Boyd","year":"2023","unstructured":"Boyd, N. K. et al. Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder. J Neurodev Disord 15, 35 https:\/\/doi.org\/10.1186\/s11689-023-09503-y (2023).","journal-title":"J Neurodev Disord"},{"key":"1921_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley, G. et al. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. J. Child Neurol. 30, 1147\u20131152 https:\/\/doi.org\/10.1177\/0883073814554654 (2015).","journal-title":"J. Child Neurol."},{"key":"1921_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/brainsci7060057","volume":"7","author":"C Mircher","year":"2017","unstructured":"Mircher, C. et al. Acute regression in young people with Down syndrome. Brain Sci. 7, 57 https:\/\/doi.org\/10.3390\/brainsci7060057 (2017).","journal-title":"Brain Sci."},{"key":"1921_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.940175","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro, J. D. et al. Assessment and diagnosis of Down syndrome regression disorder: international expert consensus. Front. Neurol. 13, 940175 https:\/\/doi.org\/10.3389\/fneur.2022.940175 (2022).","journal-title":"Front. Neurol."},{"key":"1921_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s10803-023-06057-9","volume":"55","author":"JD Santoro","year":"2023","unstructured":"Santoro, J. D. et al. Alternative diagnoses in the work up of Down syndrome regression disorder. J. Autism Dev. Disord. 55, 2085\u20132091, https:\/\/doi.org\/10.1007\/s10803-023-06057-9 (2023).","journal-title":"J. Autism Dev. Disord."},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/s1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea, J. et al. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 20, 930\u2013942 https:\/\/doi.org\/10.1016\/s1474-4422(21)00245-3 (2021).","journal-title":"Lancet Neurol."},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"e2435018","DOI":"10.1001\/jamanetworkopen.2024.35018","volume":"7","author":"E Rubenstein","year":"2024","unstructured":"Rubenstein, E. et al. Alzheimer dementia among individuals with Down syndrome. JAMA Netw. Open 7, e2435018 https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35018 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1921_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02579-z","volume":"13","author":"JD Santoro","year":"2023","unstructured":"Santoro, J. D. et al. Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl. Psychiatry 13, 276 https:\/\/doi.org\/10.1038\/s41398-023-02579-z (2023).","journal-title":"Transl. Psychiatry"},{"key":"1921_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","volume":"14","author":"JD Santoro","year":"2022","unstructured":"Santoro, J. D. et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with Down syndrome regression disorder. J. Neurodev. Disord. 14, 35 https:\/\/doi.org\/10.1186\/s11689-022-09446-w (2022).","journal-title":"J. Neurodev. Disord."},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/dmcn.14127","volume":"61","author":"KM Cardinale","year":"2019","unstructured":"Cardinale, K. M. et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev. Med. Child Neurol. 61, 847\u2013851 https:\/\/doi.org\/10.1111\/dmcn.14127 (2019).","journal-title":"Dev. Med. Child Neurol."},{"key":"1921_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14458","volume":"21","author":"M Khalafi","year":"2025","unstructured":"Khalafi, M. et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis. Alzheimers Dement. 21, e14458 https:\/\/doi.org\/10.1002\/alz.14458 (2025).","journal-title":"Alzheimers Dement."},{"key":"1921_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65882-x","volume":"16","author":"H Huber","year":"2025","unstructured":"Huber, H. et al. Plasma p-tau217 as a biomarker of Alzheimer\u2019s disease pathology in individuals with Down syndrome. Nat. Commun. 16, 9900 https:\/\/doi.org\/10.1038\/s41467-025-65882-x (2025).","journal-title":"Nat. Commun."},{"key":"1921_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319 (2024).","journal-title":"JAMA Neurol."},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamaneurol.2024.5017","volume":"82","author":"L VandeVrede","year":"2025","unstructured":"VandeVrede, L. et al. Detection of Alzheimer neuropathology in Alzheimer and non-Alzheimer clinical syndromes with blood-based biomarkers. JAMA Neurol. 82, 344\u2013354 https:\/\/doi.org\/10.1001\/jamaneurol.2024.5017 (2025).","journal-title":"JAMA Neurol."},{"key":"1921_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/acn3.52299","volume":"12","author":"JD Santoro","year":"2025","unstructured":"Santoro, J. D. et al. Evidence of blood-brain barrier dysfunction and CSF immunoglobulin synthesis in Down Syndrome Regression Disorder. Ann. Clin. Transl. Neurol. 12, 805\u2013820 https:\/\/doi.org\/10.1002\/acn3.52299 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1921_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81819-8","volume":"14","author":"JD Santoro","year":"2024","unstructured":"Santoro, J. D. et al. Diagnostic abnormalities, disease severity and immunotherapy responsiveness in individuals with Down syndrome regression disorder. Sci. Rep. 14, 30865 https:\/\/doi.org\/10.1038\/s41598-024-81819-8 (2024).","journal-title":"Sci. Rep."},{"key":"1921_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/acn3.52023","volume":"11","author":"JD Santoro","year":"2024","unstructured":"Santoro, J. D. et al. Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder. Ann. Clin. Transl. Neurol. 11, 1034\u20131045 https:\/\/doi.org\/10.1002\/acn3.52023 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1921_CR19","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1093\/brain\/awaf133","volume":"148","author":"BJ Buehner","year":"2025","unstructured":"Buehner, B. J. et al. Medial temporal lobe atrophy in Down syndrome along the Alzheimer\u2019s disease continuum. Brain 148, 2509\u20132521 https:\/\/doi.org\/10.1093\/brain\/awaf133 (2025).","journal-title":"Brain"},{"key":"1921_CR20","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1002\/alz.12999","volume":"19","author":"M Rozalem Aranha","year":"2023","unstructured":"Rozalem Aranha, M. et al. Basal forebrain atrophy along the Alzheimer\u2019s disease continuum in adults with Down syndrome. Alzheimers Dement. 19, 4817\u20134827 https:\/\/doi.org\/10.1002\/alz.12999 (2023).","journal-title":"Alzheimers Dement."},{"key":"1921_CR21","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/s0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea, J. et al. Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet 395, 1988\u20131997 https:\/\/doi.org\/10.1016\/s0140-6736(20)30689-9 (2020).","journal-title":"Lancet"},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","volume":"79","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Detection of brain tau pathology in down syndrome using plasma biomarkers. JAMA Neurol. 79, 797\u2013807 https:\/\/doi.org\/10.1001\/jamaneurol.2022.1740 (2022).","journal-title":"JAMA Neurol."},{"key":"1921_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s1474-4422(25)00158-9","volume":"24","author":"S Janelidze","year":"2025","unstructured":"Janelidze, S. et al. Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study. Lancet Neurol. 24, 591\u2013600 https:\/\/doi.org\/10.1016\/s1474-4422(25)00158-9 (2025).","journal-title":"Lancet Neurol."},{"key":"1921_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00904-4","volume":"10","author":"I Grigg","year":"2020","unstructured":"Grigg, I. et al. Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Transl. Psychiatry 10, 228 https:\/\/doi.org\/10.1038\/s41398-020-00904-4 (2020).","journal-title":"Transl. Psychiatry"},{"key":"1921_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70016","volume":"48","author":"NX Cawley","year":"2025","unstructured":"Cawley, N. X. et al. Elevated cerebrospinal fluid total tau in Niemann-pick disease type C1: correlation with clinical severity and response to therapeutic interventions. J. Inherit Metab. Dis. 48, e70016 https:\/\/doi.org\/10.1002\/jimd.70016 (2025).","journal-title":"J. Inherit Metab. Dis."},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1055\/s-0035-1565273","volume":"46","author":"MT Kadak","year":"2015","unstructured":"Kadak, M. T. et al. Low serum level \u03b1-synuclein and tau protein in autism spectrum disorder compared to controls. Neuropediatrics 46, 410\u2013415 https:\/\/doi.org\/10.1055\/s-0035-1565273 (2015).","journal-title":"Neuropediatrics"},{"key":"1921_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2026.106370","volume":"130","author":"J Arranz","year":"2026","unstructured":"Arranz, J. et al. CSF and plasma tau biomarkers in the Down syndrome-Alzheimer\u2019s disease continuum. EBioMedicine 130, 106370 https:\/\/doi.org\/10.1016\/j.ebiom.2026.106370 (2026).","journal-title":"EBioMedicine"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01921-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01921-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:03:33Z","timestamp":1792440213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01921-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01921-y","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"541"}}